TENNOR THERAP-B (06872.HK): Rifasutenizol NDA Supplementary Data Completed
NewTimeSpace News: On 12 November 2026, TenNor Therapeutics (Suzhou) Limited (stock code: 06872) announced that its two core products, rifasutenizol (TNP-2198) and rifaquizinone (TNP-2092), have achieved multiple key research and development milestones.
Rifasutenizol is the world's first new molecular entity drug candidate developed to target Helicobacter pylori infection since the discovery of the pathogen in 1982, working through a dual-targeting mechanism that inhibits bacterial RNA polymerase and produces free radicals through nitroreductase activation. The Company has completed seven clinical trials for rifasutenizol in China, comprising two Phase I, two clinical pharmacology, two Phase II and one Phase III trials; the Phase III results were published in The Lancet Infectious Diseases on 11 September 2025. The US Food and Drug Administration has granted rifasutenizol Qualified Infectious Disease Product designation. The Company submitted marketing applications for rifasutenizol capsules to the NMPA in August 2025 and received a supplementary information notice from the Center for Drug Evaluation in June 2026; as at the date of the announcement, all supplementary information had been submitted.
Rifaquizinone is a first-in-class triple-targeting candidate for biofilm infections associated with implantable medical devices, simultaneously inhibiting bacterial RNA polymerase, DNA gyrase and DNA topoisomerase IV, with resistance frequency below 10⁻¹². Six Phase I and Phase II trials have been completed in the US and China, and the FDA has granted it Qualified Infectious Disease Product, Fast Track and Orphan Drug designations. The Company has selected intra-articular administration for prosthetic joint infection as the core priority indication; the Phase IIa proof-of-concept trial produced positive results and the multi-centre Phase IIb trial has enrolled its first patient. The Company describes itself as a late-stage biopharmaceutical company with a pipeline of eight innovative projects.
- TENNOR THERAP-B (06872.HK): Termination Deadline for Rifasutenizol Collaboration Extended to 31 July 2027
- TENNOR THERAP-B (06872.HK): prioritizes rifaquizinone intra-articular injection for PJI treatment
- TENNOR THERAP-B (06872.HK): Plans H share buyback of up to RMB 50 mln
- HK Recently Listed Stocks Watch | TENNOR THERAP-B (06872.HK): Lock-up on 3.08 Million H Shares Ends Nov 21
- TENNOR THERAP-B (06872.HK): Positive Phase IIa Proof-of-Concept Data for Rifaquizalone (TNP-2092) in Prosthetic Joint Infection; Multicenter Phase IIb Initiated